Popular Articles

PAREXEL Reaches Milestone In Management Of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patients in hundreds of programs across 80 countries. PAREXEL will be marking this milestone during the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 - June 2, 2009 in Orlando, Florida. PAREXEL"s hematology and oncology experts will be available during the ASCO meeting at Booth #1980 to discuss their capabilities to support the successful development of novel cancer treatments.

Local Food Environments Can Lead To Obesity
Living in an area with more fast food outlets and convenience stores than supermarkets and grocers has been associated with obesity in a Canadian study. Researchers writing in the open access journal BMC Public Health have shown that your local food environment can affect your weight.
News of the day
Jellyfish Shed Fluorescent Light On How The Brain Works
New research offers prospect of watching the brain as it learns. Scientists at the University of Leicester are developing new ways of studying how brain cells work -thanks to jellyfish!
Cardiovascular

HIV/AIDS Vaccine Coalition Urges Continued Funding For Research Amid Economic Crisis

A recently released AIDS Vaccine Advocacy Coalition report says that although there has been a renewed focus on discovery, innovation and basic science in vaccine research, action is needed to ensure that research funding continues during the economic downturn, VOA News reports. AVAC executive director Mitchell Warren said the report is "about putting all the pieces together ... not just the search for an AIDS vaccine, but in fact the entire HIV prevention response." He added, "[T]he good news is we have some new pieces of the puzzle, and we"re expecting additional new pieces of understanding through research this year." Warren said that AVAC believes HIV/AIDS vaccine research is in "one of the most exciting times," with "new energy, new commitment to unlocking some of the basic scientific roadblocks that have impeded our ability to find a vaccine." For example, a study released earlier this week examined efforts to produce a vaccine through genetic transfer. Regarding the study, Warren said, "It doesn"t mean we have an AIDS vaccine, but it means we have an entirely new approach to trying to deliver protection." Warren said that the field of HIV/AIDS vaccine research has shown a renewed commitment since Merck canceled its vaccine trial in 2007. According to Warren, the new AVAC report examines knowledge gained from the Merck study, which has provided "an unimaginable amount of information." Meanwhile, the effect of the economic crisis on research funding is concerning, Warren said, adding, "I believe that every dollar spent is going to be held up to a greater scrutiny as budgets tighten and as funders have to re-examine their priorities." According to Warren, without renewed funding commitments, "we will not only incur a much greater public health catastrophe, but I would argue that the economic catastrophes to come, if we don"t respond aggressively to HIV, will actually have repercussions that will ... make the economic crisis pale in comparison" (DeCapua, VOA News, 5/18). The report is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):